Ravelcare Ltd Postpones H1 FY27 Results Board Meeting to November 13

Ravelcare Ltd has postponed its board meeting for approval of unaudited H1 FY27 results from November 12 to November 13, 2026, delaying the scheduled disclosure by one day. The results will cover the half year ended September 30, 2026, and the trading window will stay closed for 48 hours after the rescheduled meeting concludes.

Why did Ravelcare postpone its H1 FY27 results meeting?

Ravelcare postponed the board meeting due to unavoidable circumstances, according to the company update. The meeting had initially been scheduled for Thursday, November 12, 2026, after Ravelcare informed BSE on November 5 that its board would consider and approve unaudited financial results for the half year ended September 30, 2026.

The rescheduled meeting is set for Friday, November 13, 2026. Ravelcare said the board will review the financial results for the quarter and half year along with the limited review report. The available disclosures do not specify the circumstances behind the change or identify any issue with the financial statements.

A one-day rescheduling changes the timing of a regulatory disclosure but does not, by itself, provide evidence about operating performance. Ravelcare has not disclosed revenue, profit, margin, cash flow, or balance-sheet figures for the September 2026 half year in the information available so far.

For investors, the key pending document remains the unaudited results and related limited review report. These will provide the formal financial update for the period once considered and approved by the board.

What will Ravelcare's board consider on November 13?

Ravelcare's board will consider and approve unaudited financial results for the half year ended September 30, 2026, together with the limited review report. The company had described the agenda as covering both quarterly and half-year financial results, though the BSE intimation specifically refers to the unaudited half-year results.

The limited review report is part of the financial-reporting process for unaudited results. Its inclusion in the board agenda indicates that the meeting is intended to complete the review and approval process before the results are disclosed to the market.

No financial outcome was included in Ravelcare's meeting postponement notice. As a result, investors cannot yet assess whether sales, operating profit, expenses, or profitability changed from the figures reported in earlier periods.

How long will Ravelcare's trading window remain closed?

Ravelcare's trading window has been closed from October 1, 2026, and will remain closed until 48 hours after the conclusion of the November 13 board meeting. The company cited the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, in connection with the restriction.

The closure applies to dealing in Ravelcare securities during the period when unpublished price-sensitive information related to the results may be available internally. The restriction is designed to support orderly disclosure and reduce the risk of trading based on information not yet available to the wider market.

The postponement extends the period before the 48-hour countdown can begin because the closure condition is linked to the conclusion of the rescheduled meeting. Ravelcare has not provided a specific calendar date or time for reopening the trading window.

The announcement does not state any share-price movement, trading-volume change, or market reaction linked to the postponement. Its immediate market relevance is therefore the revised reporting timetable and the continued insider-trading compliance restriction.

What do Ravelcare's previous disclosed figures show?

Ravelcare's previously displayed half-year figures for March 2026 showed sales of Rs. 12.56 crore and operating profit of Rs. 2.72 crore. The operating profit margin was listed at 21.66%, compared with sales of Rs. 14.58 crore, operating profit of Rs. 1.28 crore, and an 8.78% margin for March 2025.

The available data also listed expenses of Rs. 9.84 crore for March 2026, against Rs. 13.30 crore in March 2025. Profit before tax was reported at Rs. 2.73 crore for March 2026 and Rs. 1.50 crore for March 2025. These are historical figures and do not indicate the yet-to-be-disclosed September 2026 half-year performance.

Ravelcare's September 2026 shareholding pattern showed Indian promoters holding 72.94% and the public holding 27.06%. This ownership information was submitted to BSE for the period ended September 30, 2026.

The company previously held a board meeting on May 30, 2026, for audited results for the half year and financial year. The current November meeting concerns unaudited results for the next reported half-year period, making its eventual disclosure the next formal financial reference point for shareholders.

How does the delay matter to investors and market participants?

The delay matters because Ravelcare's latest financial results will be available one day later than initially scheduled, while the trading window remains shut until the prescribed period after the meeting. There is no disclosed financial figure or management commentary that would allow investors to draw conclusions about H1 FY27 performance before the results are released.

For retail investors, the announcement is principally a compliance and timing update. The rescheduled meeting does not alter the results period, which ends on September 30, 2026, and Ravelcare has not announced a change in its reporting scope or a withdrawal of the planned results disclosure.

The financial results, once released, will allow comparison with the historical March figures, including sales, expenses, operating profit, and margins. Until then, claims about improvement or deterioration in Ravelcare's business performance would not be supported by the available company information.

Conclusion

Ravelcare has moved the approval of its unaudited H1 FY27 financial results and limited review report from November 12 to November 13, 2026. The one-day postponement leaves the reporting period unchanged and does not include any new financial disclosure, while the trading window remains closed under the company's insider-trading compliance process.

Investors should watch for Ravelcare's unaudited results for the half year ended September 30, 2026, and the limited review report after the rescheduled board meeting. The next confirmed timing point is the reopening of the trading window, which will occur 48 hours after the meeting concludes.